Not-celiac Gluten (Wheat) SensitivityNCT01762566
Bioelectrical Impedance Analysis of Not-celiac Wheat Sensitivity Patients
A study testing wheat and xylose in people with Not-celiac Gluten (Wheat) Sensitivity, run by University of Palermo at 2 sites in Italy.
Trial summary
Aim of the investigators' study is to evaluate one of the symptoms described by patients affected with the so-called "not-celiac wheat sensitivity" (NCWS). NCWS patients may be defined as ones, neither celiac or allergic to wheat, who develop symptoms following wheat consumption and improve on Gluten Free Diet (GFD). Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Not-celiac Gluten (Wheat) Sensitivity
- What is being tested?
- wheat and xylose
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 2 sitesItaly
- Study dates
- Jan 2012to Dec 2013
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients, both genders, with age between 18-65 years, with gastrointestinal symptoms/signs that improved on a gluten-free diet and worsen on a wheat containing diet
- Patients testing negative for celiac disease (i.e. anti-tTG and EMA negative, and with biopsy Marsh 0-1) and wheat allergy (serum specific IgE for wheat negative)
- gluten sensitivity diagnosis confirmed with a double-blind placebo-controlled challenge with gluten or placebo
Who cannot join
- Patients diagnosed with celiac disease (positive anti-tTG and/or EMA, and positive histology - (presence of villi atrophy);
- Patients diagnosed with wheat allergy (positive serum specific IgE for wheat)
- Patients suffering from Diabetes Mellitus
- Patients with Inflammatory Bowel Diseases (Crohn's disease or ulcerative colitis)
- Patients with Helicobacter pylori infection and other gastrointestinal infection
- Pregnancy
Trial locations and contacts
2 sites in 1 country.
Italy2 sites
Internal Medicine, University Hospital of Palermo
Palermo, Palermo, 90100
Internal Medicine, "Giovanni Paolo II" Hospital
Sciacca, Agrigento
About this study
Official title: Randomized Double-Blind Placebo-Controlled Trial (Wheat vs Placebo) in Wheat Sensitive Patients for Evaluation of Bio-Markers of a Single Referred Symptom (Bloating & Swelling)
Aim of the investigators' study is to evaluate one of the symptoms described by patients affected with the so-called "not-celiac wheat sensitivity" (NCWS). NCWS patients may be defined as ones, neither celiac or allergic to wheat, who develop symptoms following wheat consumption and improve on Gluten Free Diet (GFD). Among these, patients often report the appearance of bloating and abdominal pain, and, sometimes, swelling of fingers and face, shortly after ingestion of wheat. They also refer that swelling tends to last for some hours and then to disappear on GFD. To our knowledge, this disorder has never been investigated neither proved.
For the investigators' research, the investigators selected adult patients, both genders, affected with NCWS. Diagnostic criteria include: 1) symptoms disappearance on GFD, 2) testing negative for celiac disease [anti-tTG and EMA, and with biopsy Marsh 0-1] and wheat allergy [serum specific IgE for wheat], 3) positive response to a double-blind placebo-controlled challenge (DBPC) with wheat or placebo.
Read more
Patients will be recruited among subjects referring, as outpatients, to the Department of Internal Medicine, 'Giovanni Paolo II' Hospital of Sciacca (Agrigento), and of Internal Medicine of the University of Palermo, from January 2012 to October 2013. The investigators will include patients referring for functional dyspepsia and/or irritable bowel syndrome (IBS)-like symptoms. All recruited patients must report body's swelling immediately after wheat ingestion. In all recruited patients, NCWS diagnosis was posed during the previous years, according to the above mentioned criteria.
Patients, all on GFD for at least 30 days, will undergo to another DBPC with wheat or placebo (xylose), performed by administering capsules coded as A or B containing wheat or xylose, respectively. Capsules A or B will be administered once, and then, after 1 week of washout, patients received the other capsules, given once too. Before and 2 hours after every challenge, patients will undergo a complete medical examination (measurement of body weight, height, body mass index [BMI], waist circumference, diameter of thighs, legs, arms, and fingers), and we will perform bioelectrical impedance analysis and collect blood sampling, for identification of possible markers (bioelectrical, immunologic, hormonal, etc) that may help to demonstrate and explain mechanisms of examined symptom.
Read the detailed description
Gluten is the most important protein component of some grains, notably wheat, rye, and barley, which are the basis for a variety of wheat-derived alimentary products consumed throughout the world (bread, pasta, pizza etc). However the "engineering" of gluten-containing grains created the conditions for human diseases related to gluten exposure. These forms of gluten intolerance represent a heterogeneous set of conditions, including celiac disease, wheat allergy and gluten sensitivity, that, combined, seems to affect about 10% of the general population. The frequency of not-celiac gluten sensitivity is however still unknown, even though it is possible that this condition have been undiagnosed and under-diagnosed by the physicians for a long time. The immune responsiveness to wheat antigens represents a complex process, and its establishment and maintenance are not completely elucidated. The most frequent diseases caused by wheat ingestion are T cell-mediated disorders, i.e. celiac disease and immunoglobulin E (IgE)-mediated allergic reactions. However, besides celiac disease and wheat allergy, there are cases of gluten reactions in which neither autoimmune nor IgE-mediated allergic mechanisms are involved. These are generally defined as gluten sensitivity. Some subjects, who experience symptoms when eating gluten-containing products and show improvement when following a gluten-free diet, may have gluten sensitivity instead of celiac disease or wheat allergy. Gluten sensitivity patients are unable to tolerate gluten and develop an adverse reaction when eating gluten, that, usually, and differently from celiac disease, does not lead to small intestinal damage. Gastrointestinal symptoms in gluten sensitivity patients may resemble those associated with celiac disease, but the overall clinical picture is generally less severe and is not accompanied by the occurrence of autoantibodies (i.e. anti-tissue transglutaminase, tTG, or anti-endomysium, EMA) or autoimmune disease (i.e. Hashimoto's thyroiditis). Typically, the diagnosis is made by exclusion, and an elimination diet and an "open challenge" (i.e., the monitored reintroduction of gluten-containing foods) are most often used to evaluate whether health improves or worsen with the elimination or reintroduction of gluten in the diet, respectively.
As it is not known what cereals components determine the symptoms in the so called gluten sensitivity patients, we prefer to define this condition as "wheat sensitivity" instead of "gluten sensitivity".
Wheat sensitivity can cause both gastrointestinal and extra-intestinal symptoms; among the latter, the patients often reported body's swelling (hands', fingers', arms' , face's swelling).
This study has two major aims:
- Evaluation of the effective dependence from the wheat ingestion of the clinical alterations presented by patients with diagnosed gluten sensitivity, with particular attention to abdominal bloating and body's swelling. The study will be done after a period of gluten-free diet (at least 30 days), using a double-blind placebo-controlled challenge with wheat or placebo (xylose), performed by administering capsules coded as A or B containing wheat or xylose, respectively. Capsules A or B will be administered once, and then, after 1 week of washout, the patients received the other capsules, given once too.
- Before and 2 hours after every challenge, patients will undergo a complete medical examination, and The investigators will perform bioelectrical impedance analysis and collect blood sampling, for identification of possible markers that may be of help to demonstrate and explain the mechanisms of the examined symptom.
- Conditions
- Not-celiac Gluten (Wheat) Sensitivity
- Being tested
- wheat, xylose
- Keywords
- Not-celiac gluten (wheat) sensitivity, Bioelectrical impedance analysis, Bloating, Swelling
- Medical subject headings
- Hypersensitivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
wheatDietary supplement
wheat is administered blindly versus placebo in capsules once
xyloseDietary supplement
placebo (xylose) will be administered blindly versus wheat in a capsule once
| Study group | Role | What they receive |
|---|---|---|
| wheat | Active comparator | wheat is administered blindly versus placebo in capsules once Receives: Dietary Supplement: wheat; Dietary Supplement: xylose |
| xylose | Placebo comparator | placebo (xylose) will be administered blindly versus wheat in capsules once Receives: Dietary Supplement: wheat; Dietary Supplement: xylose |
What is being measured
The primary outcome is the main question the study is designed to answer.
Symptom evaluation
Symptom evaluation, before and after the challenge, by complete medical examination, with measurement of body weight, height, body mass index (BMI), waist circumference, diameter of thighs, legs, arms, and fingers
Measured: Change from baseline and at 2 hours
Secondary outcomes (1)
Bio-Markers evaluation
Bio-Markers to that may be of help to demonstrate and explain the mechanisms of the examined symptom.
Measured: Change from baseline and at 2 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jan 2013 (estimated)
- Study startJan 2012
- Primary completionOct 2013
- Study completionDec 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Not-celiac Gluten (Wheat) SensitivityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Palermo
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Pasquale Mansueto, University of Palermo
- Investigators
- Antonio Carroccio, PHD, Principal investigator, Internal Medicine, Giovanni Paolo II Hospital of Sciacca (Agrigento) and University of Palermo, Palermo, Italy
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01762566
- Sponsor's protocol ID
- ACPM02
- Status last verified
- Sep 2014
- First submitted
- 4 Jan 2013
- Last updated
- 16 Sep 2014
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Double-Blind Placebo-Controlled Trial (Wheat vs Placebo) in Wheat Sensitive Patients for Evaluation of Bio-Markers of a Single Referred Symptom (Bloating & Swelling)
- ClinicalTrials.gov ID
- NCT01762566
- Acronym / sponsor ID
- ACPM02
- Conditions
- Not-celiac Gluten (Wheat) Sensitivity
- Keywords
- Not-celiac gluten (wheat) sensitivity, Bioelectrical impedance analysis, Bloating, Swelling
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- University of PalermoUniversity, hospital or other
- Study start
- Jan 2012
- Primary completion
- Oct 2013 (actual)
- Study completion
- Dec 2013 (actual)
- First posted
- 7 Jan 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aim of the investigators' study is to evaluate one of the symptoms described by patients affected with the so-called "not-celiac wheat sensitivity" (NCWS). NCWS patients may be defined as ones, neither celiac or allergic to wheat, who develop symptoms following wheat consumption and improve on Gluten Free Diet (GFD). Among these, patients often report the appearance of bloating and abdominal pain, and, sometimes, swelling of fingers and face, shortly after ingestion of wheat. They also refer that swelling tends to last for some hours and then to disappear on GFD. To our knowledge, this disorder has never been investigated neither proved.
For the investigators' research, the investigators selected adult patients, both genders, affected with NCWS. Diagnostic criteria include: 1) symptoms disappearance on GFD, 2) testing negative for celiac disease [anti-tTG and EMA, and with biopsy Marsh 0-1] and wheat allergy [serum specific IgE for wheat], 3) positive response to a double-blind placebo-controlled challenge (DBPC) with wheat or placebo.
Patients will be recruited among subjects referring, as outpatients, to the Department of Internal Medicine, 'Giovanni Paolo II' Hospital of Sciacca (Agrigento), and of Internal Medicine of the University of Palermo, from January 2012 to October 2013. The investigators will include patients referring for functional dyspepsia and/or irritable bowel syndrome (IBS)-like symptoms. All recruited patients must report body's swelling immediately after wheat ingestion. In all recruited patients, NCWS diagnosis was posed during the previous years, according to the above mentioned criteria.
Patients, all on GFD for at least 30 days, will undergo to another DBPC with wheat or placebo (xylose), performed by administering capsules coded as A or B containing wheat or xylose, respectively. Capsules A or B will be administered once, and then, after 1 week of washout, patients received the other capsules, given once too. Before and 2 hours after every challenge, patients will undergo a complete medical examination (measurement of body weight, height, body mass index [BMI], waist circumference, diameter of thighs, legs, arms, and fingers), and we will perform bioelectrical impedance analysis and collect blood sampling, for identification of possible markers (bioelectrical, immunologic, hormonal, etc) that may help to demonstrate and explain mechanisms of examined symptom.
Detailed description
Gluten is the most important protein component of some grains, notably wheat, rye, and barley, which are the basis for a variety of wheat-derived alimentary products consumed throughout the world (bread, pasta, pizza etc). However the "engineering" of gluten-containing grains created the conditions for human diseases related to gluten exposure. These forms of gluten intolerance represent a heterogeneous set of conditions, including celiac disease, wheat allergy and gluten sensitivity, that, combined, seems to affect about 10% of the general population. The frequency of not-celiac gluten sensitivity is however still unknown, even though it is possible that this condition have been undiagnosed and under-diagnosed by the physicians for a long time. The immune responsiveness to wheat antigens represents a complex process, and its establishment and maintenance are not completely elucidated. The most frequent diseases caused by wheat ingestion are T cell-mediated disorders, i.e. celiac disease and immunoglobulin E (IgE)-mediated allergic reactions. However, besides celiac disease and wheat allergy, there are cases of gluten reactions in which neither autoimmune nor IgE-mediated allergic mechanisms are involved. These are generally defined as gluten sensitivity. Some subjects, who experience symptoms when eating gluten-containing products and show improvement when following a gluten-free diet, may have gluten sensitivity instead of celiac disease or wheat allergy. Gluten sensitivity patients are unable to tolerate gluten and develop an adverse reaction when eating gluten, that, usually, and differently from celiac disease, does not lead to small intestinal damage. Gastrointestinal symptoms in gluten sensitivity patients may resemble those associated with celiac disease, but the overall clinical picture is generally less severe and is not accompanied by the occurrence of autoantibodies (i.e. anti-tissue transglutaminase, tTG, or anti-endomysium, EMA) or autoimmune disease (i.e. Hashimoto's thyroiditis). Typically, the diagnosis is made by exclusion, and an elimination diet and an "open challenge" (i.e., the monitored reintroduction of gluten-containing foods) are most often used to evaluate whether health improves or worsen with the elimination or reintroduction of gluten in the diet, respectively.
As it is not known what cereals components determine the symptoms in the so called gluten sensitivity patients, we prefer to define this condition as "wheat sensitivity" instead of "gluten sensitivity".
Wheat sensitivity can cause both gastrointestinal and extra-intestinal symptoms; among the latter, the patients often reported body's swelling (hands', fingers', arms' , face's swelling).
This study has two major aims:
- Evaluation of the effective dependence from the wheat ingestion of the clinical alterations presented by patients with diagnosed gluten sensitivity, with particular attention to abdominal bloating and body's swelling. The study will be done after a period of gluten-free diet (at least 30 days), using a double-blind placebo-controlled challenge with wheat or placebo (xylose), performed by administering capsules coded as A or B containing wheat or xylose, respectively. Capsules A or B will be administered once, and then, after 1 week of washout, the patients received the other capsules, given once too.
- Before and 2 hours after every challenge, patients will undergo a complete medical examination, and The investigators will perform bioelectrical impedance analysis and collect blood sampling, for identification of possible markers that may be of help to demonstrate and explain the mechanisms of the examined symptom.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| wheat | Active comparator | Dietary Supplement: wheat, Dietary Supplement: xylosewheat is administered blindly versus placebo in capsules once |
| xylose | Placebo comparator | Dietary Supplement: wheat, Dietary Supplement: xyloseplacebo (xylose) will be administered blindly versus wheat in capsules once |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adult patients, both genders, with age between 18-65 years, with gastrointestinal symptoms/signs that improved on a gluten-free diet and worsen on a wheat containing diet
- Patients testing negative for celiac disease (i.e. anti-tTG and EMA negative, and with biopsy Marsh 0-1) and wheat allergy (serum specific IgE for wheat negative)
- gluten sensitivity diagnosis confirmed with a double-blind placebo-controlled challenge with gluten or placebo
Key exclusion criteria (6 listed)
- Patients diagnosed with celiac disease (positive anti-tTG and/or EMA, and positive histology - (presence of villi atrophy);
- Patients diagnosed with wheat allergy (positive serum specific IgE for wheat)
- Patients suffering from Diabetes Mellitus
- Patients with Inflammatory Bowel Diseases (Crohn's disease or ulcerative colitis)
- Patients with Helicobacter pylori infection and other gastrointestinal infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| wheatwheat is administered blindly versus placebo in capsules once | Dietary supplement | wheat, xylose |
| xyloseplacebo (xylose) will be administered blindly versus wheat in a capsule once | Dietary supplement | wheat, xylose |
Primary outcome
Symptom evaluation
Time frame: Change from baseline and at 2 hours
Symptom evaluation, before and after the challenge, by complete medical examination, with measurement of body weight, height, body mass index (BMI), waist circumference, diameter of thighs, legs, arms, and fingers
1 secondary outcome
Bio-Markers evaluation
Time frame: Change from baseline and at 2 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2014.
Related trials for Not-celiac Gluten (Wheat) Sensitivity
Recruiting
Bio-markers of Not-celiac Wheat Sensitivity
Not-celiac Wheat Sensitivity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Antonio Carroccio, PHD principal investigator
Internal Medicine, Giovanni Paolo II Hospital of Sciacca (Agrigento) and University of Palermo, Palermo, Italy
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing wheat and xylose in people with Not-celiac Gluten (Wheat) Sensitivity, run by University of Palermo at 2 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Sep 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Symptom evaluation (time frame: Change from baseline and at 2 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2014.